https://www.selleckchem.com/pr....oducts/Cryptotanshin
There was no difference in CR (p = 0.9 or time to CR (p = 0.31) between the treatment cohorts. Overall, 22% experienced a disease recurrence. On multivariable analysis, EC histology was the only covariate associated with a decreased Prog response (HR 0.48; p = 0.007). Only 17% of the cohort achieved a live-birth pregnancy, the majority of which required assisted reproductive technologies (81%) and occurred in the Prog treatment group. CONCLUSIONS Our study does not support the use of Prog-Met therapy for treatment of AH/EIN o
Beğen
Yorum Yap
Paylaş
